Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 4;8(4):176.
doi: 10.3390/pathogens8040176.

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence

Fabrizio Fabrizi  1 , Roberta Cerutti  2 , Giulia Porata  3 , Piergiorgio Messa  4   5 , Ezequiel Ridruejo  6   7   8
Affiliations
Review

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence

Fabrizio Fabrizi et al. Pathogens. .

Abstract

Glomerular disease is an extra-hepatic manifestation of hepatitis C virus infection (HCV) and membranoproliferative glomerulonephritis is the most frequent glomerular disease associated with HCV. It occurs commonly in patients with HCV-related mixed cryoglobulinemia syndrome. Patients with HCV-related glomerular disease have been historically a difficult-to-treat group. The therapeutic armamentarium for HCV-related glomerular disease now includes antiviral regimens, selective or non-specific immunosuppressive drugs, immunomodulators, and symptomatic agents. The treatment of HCV-associated glomerular disease is dependent on the clinical presentation of the patient. The recent introduction of all-oral, interferon (IFN)-free/ribavirin (RBV)-free regimens is dramatically changing the course of HCV in the general population, and some regimens have been approved for HCV even in patients with advanced chronic kidney disease. According to a systematic review of the medical literature, the evidence concerning the efficacy/safety of direct-acting antiviral agents (DAAs) of HCV-induced glomerular disease is limited. The frequency of sustained virological response was 92.5% (62/67). Full or partial clinical remission was demonstrated in many patients (n = 46, 68.5%) after DAAs. There were no reports of deterioration of kidney function in patients on DAAs. Many patients (n = 29, 43%) underwent immunosuppression while on DAAs. A few cases of new onset or relapsing glomerular disease in patients with HCV successfully treated with DAAs have been observed. In summary, DAA-based combinations are making easier the management of HCV. However, patients with HCV-induced glomerular disease are still a difficult-to-treat group even at the time of DAAs.

Keywords: direct-acting antiviral agents; glomerulonephritis; hepatitis C virus; mixed cryoglobulinemia; proteinuria; sustained virological response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
HCV RNA genome structure and targets for DAAs.
Figure 2
Figure 2
Purpuric manifestations in the legs after successful therapy with DAAs.
See this image and copyright information in PMC

References

    1. Fabrizi F., Plaisier E., Saadoun D., Martin P., Messa P., Cacoub P. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am. J. Kidney Dis. 2013;61:623–637. doi: 10.1053/j.ajkd.2012.08.040. - DOI - PubMed
    1. Rutledge S., Chung T., Sise M. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodial. Int. 2018;22:S81–S96. doi: 10.1111/hdi.12649. - DOI - PubMed
    1. Kidney Disease Improving Global Outcomes (KDIGO) Hepatitis C Work Group KDIGO 2018 Clinical Pratice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. Suppl. 2018;8:91–165. doi: 10.1016/j.kisu.2018.06.001. - DOI - PMC - PubMed
    1. Kasuno K., Ono T., Matsumori A., Nogaki F., Kusano H., Watanabe H., Yodoi J., Muso E. Hepatitis C virus-associated tubulo-interstitial injury. Am. J. Kidney Dis. 2003;41:767–775. doi: 10.1016/S0272-6386(03)00024-6. - DOI - PubMed
    1. Fabrizi F., Donato F., Messa P. Association between hepatitis C virus and chronic kidney disease: A systematic review and meta-analysis. Ann. Hepatol. 2018;17:364–391. doi: 10.5604/01.3001.0011.7382. - DOI - PubMed